ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

NextEdge Admin

16 Nov 2024

2 min 32 sec

The Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator (DxA) has invested $1.18 million in the University of Gothenburg to standardize phosphorylated tau 217 (p-tau217) blood tests, a key biomarker for Alzheimer’s disease. Led by Drs. Henrik Zetterberg and Nicholas Ashton, the project aims to develop certified reference materials to ensure consistency across test developers and clinical settings.

“Blood tests are transforming Alzheimer’s diagnosis and treatment,” said Dr. Howard Fillit, ADDF Co-Founder and Chief Science Officer. “Standardization is essential to provide reliable diagnostics globally, enabling patients to access accurate treatments for this debilitating disease.”

Building on successes with cerebrospinal fluid biomarkers like amyloid beta 1-42 (Aβ42) and total tau (t-tau), this initiative seeks to extend these advancements to blood tests, offering a critical step toward widespread diagnostic accessibility. Standardized p-tau217 assays will enhance diagnostic precision and advance research into Alzheimer’s underlying biology and treatment.

“Standardizing p-tau217 is urgently needed for global clinical adoption,” said Dr. Zetterberg. “This DxA investment underscores the importance of evidence-based guidelines in enabling uniform and reliable assays.”

The DxA has invested over $70 million in nearly 70 projects, including initiatives for retinal scans and digital tools, highlighting its commitment to accessible, scalable Alzheimer’s diagnostics. These innovations aim to support early detection, prognostic assessments, and prevention efforts.

As Alzheimer’s research progresses, standardized biomarkers like p-tau217 will be critical for precision medicine approaches, similar to personalized treatments in cancer care. These tools lay the foundation for combination therapies, offering new hope for patients and ensuring continued momentum in Alzheimer’s diagnostics and treatment innovation.